News
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO
Published: 1st February 2024
Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field.
Read more
3P Biopharmaceuticals: building a legacy of innovation and excellence in biotechnology
Published: 20th December 2023
At the International Congress of High Impact Entrepreneurship, orchestrated by the European Business and Innovation Center of Navarra (CEIN), 3P Biopharmaceuticals (3P) emerges as the winner of the "Best Track Record in the CEIN incubators" award
Read more
3P Biopharmaceuticals and the University of Navarra bring the Neanderthal world and biomedicine to the public in a successful event.
Published: 19th October 2023
This afternoon Pamplona became the epicentre of knowledge and innovation in the field of biomedicine, thanks to the event "Exploring our shared legacy between Neanderthals and Sapiens: challenges and uncertainties of future biomedicine", organized by 3P Biopharmaceuticals in collaboration with the Faculty of Pharmacy and Nutrition of the University of Navarra.
Read more
3P Biopharmaceuticals celebrates Cerebral Palsy Day in collaboration with Aspace
Published: 6th October 2023
As part of World Cerebral Palsy Day, 3P Biopharmaceuticals is extremely proud to celebrate its ongoing commitment to inclusion and social development through this valuable collaboration with Aspace's industrial laundry.
Read more
3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.
Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more
3P Biopharmaceuticals lands in the United States.
Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more
3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.
Published: 2nd May 2023
The process transfer and GMP supply of the
FGF-1 candidate have been achieved successfully by both companies.
Read more
The Regional Minister for Economic and Business Development Mikel Irujo meets with the management of 3P Biopharmaceuticals and its majority shareholder Keensight Capital.
Published: 23rd March 2023
During the meeting, attendees evaluated 3P's trajectory and its investment plan for the next five years.
Read more
3P Biopharmaceuticals is moving forward with its expansion plan and the adaptation of its facilities.
Published: 9th March 2023
The biotechnology company from Navarra opens its third installation in Noáin.
Read more